Foetal lipoprotein oxidation and preeclampsia.

L A Gil-Acevedo, Guillermo Ceballos, Y D Torres-Ramos

Journal: Lipids in health and disease 2022;21(1):51

PMID: 35658865

Abstract

Preeclampsia (PE) is a multisystemic syndrome specific to pregnancy. Although PE is the leading cause of death from complications associated with pregnancy, its aetiology is still unknown. In PE, lipid metabolism is altered. When lipids are damaged, both the mother and the foetus may be at risk. Lipoproteins contain apolipoproteins, triacylglycerols, free and esterified cholesterol, and phospholipids, all of which are susceptible to oxidative stress when high levels of oxygen and nitrogen free radicals are present. Lipoperoxidation can occur in three stages: mild, moderate, and severe. In severe lipid damage, highly toxic products such as malondialdehyde (MDA) can be generated; under these conditions, low-density lipoprotein (LDL) proteins can be oxidized (oxLDL). oxLDL is a biomolecule that can affect the production of nitric oxide (NO), the main vasodilator derived from the endothelium. oxLDL can interfere with the transduction of the signals responsible for triggering the activation of endothelial nitric oxide synthase (eNOS), causing reduced vasodilation and endothelial dysfunction, which are the main characteristics of preeclampsia. The objective of the review was to analyse the information the current information about exists about the impact generated by the oxidation of LDL and HDL lipoproteins in neonates of women with preeclampsia and how these alterations can predispose the neonate to develop diseases in adulthood.PE can cause foetal loss, intrauterine growth restriction, or developmental complications. Neonates of mothers with PE have a high risk of cardiovascular diseases, stroke, mental retardation, sensory deficiencies and an increased risk of developing metabolic diseases. PE not only affects the foetus, generating complications during pregnancy but also predisposes them to chronic diseases in adulthood.

© 2022. The Author(s).

Address: Laboratorio Central, Instituto Nacional de Perinatología Isidro Espinosa de los Reyes, Secretaría de Salud, Montes Urales 800, Lomas Virreyes, Miguel Hidalgo, 11000, Ciudad de México, Mexico.; Escuela Superior de Medicina, unidad de posgrado, Instituto Politécnico Nacional, Salvador Díaz Mirón, Esq. Plan de San Luis S/N, Miguel Hidalgo, Casco de Santo Tomas, 11340, Ciudad de México, México.; Laboratorio de Investigación Integral Cardiometabólica, Escuela Superior de Medicina, Instituto Politécnico Nacional, Salvador Díaz Mirón, Esq. Plan de San Luis S/N, Miguel Hidalgo, Casco de Santo Tomas, 11340, Ciudad de México, México.; Departamento de Inmunobioquímica, Instituto Nacional de Perinatología Isidro Espinosa de los Reyes, Secretaría de Salud. Montes Urales 800, Lomas Virreyes, Miguel Hidalgo, 11000, Ciudad de México, México. [email protected].
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.